medigraphic.com
ISSN 2520-9078 (Electronic)

2021, Number 1

<< Back Next >>

Revista de Ciencias Médicas de la Habana 2021; 28 (1)

Management of COVID -19 in Cuba. Its relation with immunology

Rodríguez LIR, Hernández GE

Language: Spanish
References: 34
Page: 105-122
PDF size: 1137.29 Kb.


ABSTRACT

Introduction: Critical moments are lived in the history of humanity. In Cuba, isolation has been tried to.
Objective: To describe new treatments to fight this disease and relate them with immunologic mechanisms.
Methods: An integrated library research was performed. The criterion of selection was the updated current literature, a basic clinical link between the discipline Immunology and protocols was treated. The National Medical Sciences Information Center, the WHO web sites; national and international on line magazines on data Bases such as Pubmed/Medline, Elsevier and in Google Scholar were consulted.
Conclusions: Not there is specific established treatment, taking national and international experiences, Cuba approves protocols and measures that respond to the basic clinical interaction in the professional development.


REFERENCES

  1. Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends [Internet]. 2020 Mar [citado 17 Abr 2020];14(1):64-8. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32037389/

  2. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med [Internet]. 2020 [citado 17 Abr 2020];1-10. Disponible en: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2763184

  3. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected [Internet]. Ginebra: World Health Organization; 2020 [citado 17 Abr 2020]. Disponible en: https://apps.who.int/iris/rest/bitstreams/1279870/retrieve

  4. Pan H, Zhang G, Zhang G, Hu C, Luo L, Fang F, et al. Clinical features and treatment of 221 patients with COVID-19 in Wuhan, China. Lancet Infect Dis [Internet]. 2020 [citado 17 Abr 2020]:1–37. Disponible en: https://www.researchgate.net/publication/340549706_Clinical_features_and_short-term_outcomes_of_221_patients_with_COVID-19_in_Wuhan_China

  5. Ludvigsson JF. Systematic review of COVID-19 in children show milder cases and a better prognosis than adults. Acta Paediatr [Internet]. 2020 [citado 17 Abr 2020];109(6);100-3. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/32202343

  6. Centro Nacional de Información de Ciencias Médicas. Actualización epidemiológica. Nuevo coronavirus (2019-nCoV) [Internet]. La Habana: Centro Nacional de Información de Ciencias Médicas; 2020 [citado 17 Abr 2020]. Disponible en: https://www.paho.org/es/file/58298/download?token=VbunRrlR

  7. Baynes J, Dominiczak MH. Bioquímica Médica. Libro de Consulta 5ta ed. Columbia: El Sevier; 2019.

  8. Gómez Tejeda JJ, Dieguez Guach RA, Pérez Abreu MR. Alternativas terapéuticas para el manejo de la COVID-19. Rev haban cienc méd [Internet]. 2020 [citado 17 Abr 2020];19(Supl.):e3328. Disponible en: http://www.revhabanera.sld.cu/index.php/rhab/article/view/3328/2577

  9. X. Li. Molecular immune pathogenesis and diagnosis of COVID-19. Journal of Pharmaceutical Analysis [Internet]. 2020 [citado 17 Abr 2020];10(1). Disponible en: https://www.sciencedirect.com/science/article/pii/S2095177920302045

  10. Sanders J. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): a review. JAMA [Internet]. 2020 Abr [citado 17 Abr 2020];323. Disponible en: https://jamanetwork.com/journals/jama/fullarticle/2764727

  11. Pérez Martín OG, Vega García IG. Inmunología en el humano sano. La Habana: Editorial Ciencias Médicas; 2017.

  12. Cardellá Rosales L, Fernández Hernández R. Bioquímica Médica. Metabolismo intermediario y su regulación. La Habana: Editorial Ciencias Médicas; 1999.

  13. World Health Organization. Pneumonia of unknown cause-China [Internet]. Berna: World Health Organization; 2020 [citado 13 Mar 2020]. Disponible en: https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/

  14. Caballero A, Caballero AD. Síndrome de distrés respiratorio agudo. En: Caballero A, Domínguez M, Pardo A, Abdo A, eds. Terapia Intensiva [Internet]. La Habana: Ecimed: 2019 [citado 13 Mar 2020]:132-81. Disponible en: http://medisur.sld.cu/index.php/medisur/article/view/3601/2755

  15. Gautret P, Lagier JC, Parola P, Thuan Hoang V, Meddeb L, Mailhe M. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non randomized clinical trial. Int J Antimicrob Agents [Internet]. 2020 Mar [citado 13 Mar 2020];55. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102549/

  16. Coutard B. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furinlike cleavage site absent in CoV of the same clade. Antiviral Research [Internet]. 2020 Abr [citado 13 Mar 2020];176. Disponible en: https://doi.org/10.1016/j.antiviral.2020.104742

  17. B. Coutarda C, Valleb X, de Lamballeriea B, Canardb NG, Seidahc E. Coronavirus membrane fusion mechanism offers as a potential target for antiviral development. Antiviral Research [Internet]. 2020 Apr [citado 17 Abr 2020];178. Disponible en: https://doi.org/10.1016/j.antiviral.2020.104792

  18. Gendrot M, Javelle E, Le Dault E, Clerc A, Savini H, Pradines B. Chloroquine as prophylactic agent against COVID-19. Int J of Antimicrobial Agents [Internet]. 2020 [citado 16 Abr 2020];55. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152897/

  19. Cortegiani G, Ingoglia MI. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. Journal of Critical Care [Internet]. 2020 Mar [citado 20 Abr 2020];55. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32173110/

  20. Fantini J, Di Scala Cl. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Int J Antimicrobial Agents [Internet]. 2020 Abr [citado 17 Abr 2020];55(5). Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0924857920301102

  21. Cepero Llauger K, Pardo Ramírez I, Gómez León M. Respuesta inmunitaria y trombótica en pacientes con síndrome de dificultad respiratoria aguda en la neumonía por SARS-CoV-2. Anales de la Academia de Ciencias de Cuba [Internet]. 2020 [citado 14 May 2020];10(2). Disponible en: http://www.revistaccuba.sld.cu/index.php/revacc/article/view/782/820

  22. Gauna ME, Bernava JL. Recomendaciones diagnostica y terapéuticas ante la Respuesta Inmune Trombótica Asociada a COVID-19 (RITAC). CorSalud [Internet]. 2020 [citado 14 May 2020];12(1):60-3. Disponible en: http://www.revcorsalud.sld.cu/index.php/cors/article/view/615/1096

  23. Guyton AC, Hall JE. Fisiología Médica. 11ed. New York: Editorial Elsevier Saunders; 2017.

  24. Kumar V, Abbas AK, Fausto N, Aster JC. Pathologic Basis of Disease. 8va ed. India: Editorial Elsevier. 2010.

  25. Carlos WG, Cruz CSD, Cao B, Pasnick S, Jamil S. Novel Wuhan (2019-nCoV) Coronavirus. Am J Respir Critic Care Med [Internet]. 2020 [citado 14 May 2020];201(4):7-8. Disponible en: https://salud.edomex.gob.mx/hraez/documentos/ensenanza_inv/covid/epidemiologia/Novel_Wuhan_2019-nCoV_Coronavirus.pdf

  26. Ministerio de Salud Pública. Protocolo Nacional MINSAP vs COVID-19 [Internet]. La Habana: MINSAP; 2020 [citado 14 May 2020]. Disponible en: https://covid19cubadata.github.io/protocolos/protocolo-version-2.pdf

  27. Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio [Internet]. 2018 [citado 14 May 2020];9(2). Disponible en: https://mbio.asm.org/content/9/2/e00221-18

  28. Clinical Trials Arenal [Internet]. London: ©Copyright 2021 Verdict Media Limited; 2021 [citado 14 May 2020]. Disponible en https://www.clinicaltrialsarena.com/projects/remdesivir/#:~:text=Credit%3A%20NIAID%20RML.,Remdesivir%20is%20an%20investigational%20antiviral%20drug%20being%20developed%20by%20Gilead,approved%20for%20any%20indication%20globally.

  29. Jin Y-H, Cai L Cheng ZS, Cheng H, Deng T, Fan Y-P, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res [Internet]. 2020 [citado 14 May 2020];7(1):4. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003341/ 30.Hoffmann M, Kleine Weber H, Schroeder S Krüger N, Herrler T, Erichsen S, Erichsen S, et al. SARSCoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell [Internet]. 2020 [citado 27 Abr 2020];16;181(2):271-80.e8. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102627/

  30. Carsana L, Sonzogni A, Nasr A, Rossi RS, Pellegrinelli A, Zerbi P, et al. Pulmonary post-mortem findings in a large series of COVID-19 cases from Northern Italy: a two-centre descriptive study. The lancet. [Internet]. 2020 [Citado 27/09/2020]; 20:1135–40. Disponible en: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30434-5/fulltext

  31. Wu Z, Mc Googan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the chinese center for disease control and prevention. JAMA [Internet]. 2020 [citado 20 Abr 2020];323(13):1239-42. Disponible en: https://jamanetwork.com/journals/jama/fullarticle/2762130

  32. Díaz Casañas E, Rodriguez Moya VS, Montes de Oca Martínez N. Surfactante pulmonar: posible intervención frente al nuevo Síndrome Respiratorio Agudo Severo Coronavirus 2 (SARS-CoV-2). Rev haban cienc méd [Internet]. 2020 [citado 10 Mar 2021]; 19(0). Disponible en: http://www.revhabanera.sld.cu/index.php/rhab/article/view/3361

  33. Blanco Hidalgo O, Beltrán Núñez A, González Rodríguez D, Sánchez Calero J, Fernández Limia O, Faure García R, et al. Some anti-inflammatory properties of a natural pulmonary surfactan: Surfacen. Applied Cardiopulmonary Pathophysiology [Internet]. 2000 [citado 20 Abr 2020];9(3):201-2. Disponible en: https://cronfa.swan.ac.uk/Record/cronfa19714/Description

  34. Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest [Internet]. 2021 [citado 4 May 2020];130(4):1545-8. Disponible en: http://www.sah.org.ar/pdf/covid-19/138003_2-20200318025412-covered-253bed37ca4c1ab43d105aefdf7b5536.pdf




2020     |     www.medigraphic.com